Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care – results from the Dresden NOAC registry

AIM: Vitamin-K antagonists (VKA) and non-vitamin-K dependent oral anticoagulants (NOAC) have been approved for anticoagulation in venous thromboembolism (VTE) and atrial fibrillation and patients previously treated with VKA are switched to NOAC therapy. Safety data for this switching are urgently ne...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Clin Pharmacol
Auteurs principaux: Beyer-Westendorf, Jan, Gelbricht, Vera, Förster, Kati, Ebertz, Franziska, Röllig, Denise, Schreier, Thomas, Tittl, Luise, Thieme, Christoph, Hänsel, Ulrike, Köhler, Christina, Werth, Sebastian, Kuhlisch, Eberhard, Stange, Thoralf, Röder, Ingolf, Weiss, Norbert
Format: Artigo
Langue:Inglês
Publié: BlackWell Publishing Ltd 2014
Sujets:
Drug Safety
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4239984/
https://ncbi.nlm.nih.gov/pubmed/24697922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12391
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires